Bull Harbor Capital LLC Acquires New Holdings in Medpace Holdings, Inc. $MEDP

Bull Harbor Capital LLC bought a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) during the first quarter, Holdings Channel.com reports. The institutional investor bought 2,093 shares of the company’s stock, valued at approximately $1,005,000.

Other hedge funds also recently bought and sold shares of the company. NewEdge Advisors LLC increased its position in shares of Medpace by 22.1% during the first quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock valued at $319,000 after acquiring an additional 190 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Medpace by 3.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock valued at $24,929,000 after acquiring an additional 3,010 shares during the period. Geneos Wealth Management Inc. raised its stake in shares of Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares during the period. Sivia Capital Partners LLC acquired a new position in shares of Medpace in the 2nd quarter worth approximately $296,000. Finally, M&T Bank Corp lifted its holdings in shares of Medpace by 3.4% in the 2nd quarter. M&T Bank Corp now owns 939 shares of the company’s stock worth $295,000 after acquiring an additional 31 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Insiders Place Their Bets

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of the company’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the sale, the general counsel owned 20,343 shares in the company, valued at $9,154,350. This represents a 44.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO August J. Troendle sold 3,510 shares of the stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $600.01, for a total value of $2,106,035.10. Following the completion of the sale, the chief executive officer directly owned 638,946 shares in the company, valued at $383,373,989.46. This represents a 0.55% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 31,087 shares of company stock worth $16,203,054 in the last quarter. 20.50% of the stock is owned by company insiders.

Medpace Stock Up 2.5%

NASDAQ:MEDP opened at $585.49 on Thursday. The company has a fifty day simple moving average of $501.76 and a two-hundred day simple moving average of $493.30. The company has a market cap of $16.34 billion, a price-to-earnings ratio of 34.32, a price-to-earnings-growth ratio of 2.55 and a beta of 1.15. Medpace Holdings, Inc. has a 52 week low of $373.00 and a 52 week high of $677.90.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.98 by $0.27. The business had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same period last year, the firm earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, analysts expect that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Wall Street Analyst Weigh In

MEDP has been the subject of a number of research analyst reports. Barclays set a $600.00 price objective on shares of Medpace in a research report on Thursday, July 23rd. Mizuho boosted their target price on Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Royal Bank Of Canada upped their price target on Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. Leerink Partners set a $620.00 price target on Medpace in a research report on Thursday, July 23rd. Finally, BMO Capital Markets lifted their price objective on Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a research note on Friday, July 24th. Two research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $584.18.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.